In this article, Dr Clair Brooks, Applications Specialist, and Matthew Fenn, Head of Business Development, discuss the development and validation of the Alberta Idealised Nasal Inlet (AINI), exploring how it can be used to optimise intranasal drug delivery and provide a realistic assessment of pulmonary deposition risk.
This article is taken from from Inhalation Magazine April 2024.
